ARGX (argenx SE) Buildings And Improvements : $0 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is argenx SE Buildings And Improvements?

argenx SE's quarterly buildings and improvements increased from Sep. 2024 ($0 Mil) to Dec. 2024 ($49 Mil) but then declined from Dec. 2024 ($49 Mil) to Mar. 2025 ($0 Mil).

argenx SE's annual buildings and improvements increased from Dec. 2022 ($20 Mil) to Dec. 2023 ($29 Mil) and increased from Dec. 2023 ($29 Mil) to Dec. 2024 ($49 Mil).

argenx SE Buildings And Improvements Historical Data

The historical data trend for argenx SE's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Buildings And Improvements Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Get a 7-Day Free Trial

11.72

16.46

19.82

28.59

48.99

argenx SE Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	48.99	-

argenx SE Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.